Drug Search Results
More Filters [+]

VDMN-21

Alternative Names: VDMN-21, VDMN 21, VDMN21
Latest Update: 2024-11-18
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Transdermal

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Veradermics, Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for VDMN-21

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Warts

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Protocol 250-1951-201

P2

Active, not recruiting

Warts

2024-12-01

Recent News Events

Date

Type

Title